Evommune, Inc. files regulatory documents covering its clinical-stage biotechnology business, public-company governance and capital structure. Its 8-K filings furnish operating and financial results, Regulation FD corporate presentations, material-event disclosures and clinical updates for pipeline programs including EVO756 and EVO301.
Evommune’s SEC record also includes registration materials tied to common stock offerings and proxy materials for annual meeting matters. These filings document director elections, auditor ratification, shareholder voting procedures, capital-structure disclosures, material agreements, clinical and regulatory disclosures, and risk factors associated with developing therapies for chronic inflammatory diseases.
Evommune, Inc. Chief Financial Officer Kyle Carver reported an option exercise and related share sale. On May 28, he exercised options to acquire 15,000 shares of common stock at $2.99 per share and sold 18,175 shares of common stock in open-market transactions at a weighted average price of $22.84 per share.
The filing states these trades were executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 26, 2026, indicating they were scheduled in advance. Following the sale, Carver directly holds 59,335 shares of Evommune common stock.
Morgan Stanley Smith Barney LLC submitted a Form 144 notice relating to EVMN securities as of 06/01/2026. The filing lists 24,225 shares (aggregate line), including sales tied to Pre-IPO purchases: 13,760 shares dated 06/22/2020 and 10,465 shares dated 12/28/2020.
EVMN: Notice of proposed resale of Common Stock under Rule 144
The excerpt lists proposed sales of Common Stock including 15,000 shares tied to an exercise of stock options with a sale date of 06/01/2026. It also shows 3,175 shares from a Pre-IPO Purchase dated 04/26/2026. The filer is identified as Morgan Stanley Smith Barney LLC Executive Financial Services on behalf of the seller.
Morgan Stanley Smith Barney LLC filed a Form 144 notice concerning 22,500 shares of common stock of EVMN proposed for sale following an Exercise of Stock Options dated 05/28/2026. The filing also lists a Pre-IPO Purchase of 3,175 shares dated 04/26/2023.
Evommune, Inc. filed a prospectus supplement to its S-1 that incorporates its Form 10-Q for the quarter ended March 31, 2026 and updates the offering materials.
The supplement discloses cash, cash equivalents and investments of approximately $307.0 million, a net loss of $21.7 million ($0.64 per share) for Q1 2026, and 36,018,372 shares outstanding as of May 5, 2026. The Company raised net proceeds of $117.2 million in February 2026 from a private placement of 4,494,279 shares at $27.88 per share and states existing resources are expected to fund operations through 2028 under its current plan.
The supplement reiterates clinical development plans: EVO756 Phase 2b CSU initial results expected June 2026, EVO756 AD initial results expected Q3 2026, planned EVO756 migraine Phase 2b start mid-2026, and EVO301 Phase 2b planned to commence mid-2027.
Evommune, Inc. reported a larger net loss for the quarter ended March 31, 2026 as it continued investing heavily in its anti-inflammatory pipeline. The company generated no revenue this quarter, compared with $3.0 million of license revenue a year earlier.
Research and development expenses rose to $17.3 million and general and administrative costs to $6.6 million, driving a net loss of $21.7 million, or $0.64 per share. Cash, cash equivalents and investments totaled $307.0 million, helped by a $117.2 million private placement, which management believes can fund operations through 2028.
The company’s lead programs, EVO756 and EVO301, are in Phase 2 development targeting chronic inflammatory diseases, with multiple Phase 2b trials underway or planned over the next several years.
Evommune, Inc. reported first-quarter 2026 results and detailed progress across its chronic inflammation pipeline. Cash, cash equivalents and investments were $307.0 million as of March 31, 2026, up from $216.7 million at year-end 2025, supporting an expected cash runway through 2028.
The company reported no revenue in Q1 2026 versus $3.0 million a year earlier, driven by lower collaboration revenue, and a net loss of $21.7 million, compared with $14.6 million in Q1 2025, as R&D and G&A spending increased.
Evommune highlighted late-stage pipeline catalysts: Phase 2b top-line data for EVO756 in chronic spontaneous urticaria is expected in June 2026 and in atopic dermatitis in the third quarter of 2026, with a Phase 2b migraine prophylaxis trial planned for mid-2026. For EVO301, positive Phase 2a proof-of-concept data in atopic dermatitis support a larger Phase 2b trial using a new subcutaneous formulation planned to start in mid-2027.
Evommune, Inc. registers 4,494,279 shares of common stock for resale by selling stockholders.
The prospectus covers the resale from time to time of up to 4,494,279 Shares by the selling stockholders; the company will not receive proceeds from these resales. Shares outstanding were 36,018,372 as of March 31, 2026.